Intra-aortic balloon pump receives FDA clearance for treatment of arrhythmias, elevated heart rate
Teleflex announced FDA clearance for an intra-aortic balloon pump for the treatment of patients with severe arrhythmias or heart rates up to 200 beats per minute, including those who were originally not candidates for the therapy.
The device (AC3 Optimus) delivers intra-aortic balloon pump therapy through an artery and into the aorta to assist in pumping blood. The console manages the inflation and deflation of the balloon. Algorithms in the device automatically regulate the timing and triggering of intra-aortic balloon pump therapy, according to a press release issued by the company.
“When a patient has an elevated heart rate or severe arrhythmia, his or her survival can suddenly depend on the ability of the [intra-aortic balloon pump] to keep pace and provide accurate therapy,” Kyle Spear, CCP, chief perfusionist at Beth Israel Deaconess Medical Center in Boston, said in the release. “[The device] does this with precision across a wide range of patient conditions.”
The intra-aortic balloon pump will be launched at the American Association for Thoracic Surgery and American Society of ExtraCorporeal Technology Annual Meeting and the EuroPCR conference in May, according to the release.
Disclosure: Spear reports receiving consultant fees from Teleflex.